
Unexpected Metastatic Localizations of Prostate Cancer Determined by <sup>68</sup>Ga PSMA PET/CT: Series of Four Cases
Author(s) -
Gözde Mütevelizade,
Ceren Sezgin,
Gül Gümüşer,
Elvan Sayıt
Publication year - 2022
Publication title -
molecular imaging and radionuclide therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.292
H-Index - 7
eISSN - 2147-1959
pISSN - 2146-1414
DOI - 10.4274/mirt.galenos.2021.41033
Subject(s) - medicine , prostate cancer , glutamate carboxypeptidase ii , nuclear medicine , metastasis , prostate , cancer , radiology
Prostate-specific membrane antigen (PSMA) is a transmembrane protein with overexpression in most prostate cancer cells. Gallium-68-( 68 Ga) PSMA positron emission tomography/computed tomography (PET/CT) imaging is a game-changer in the management of prostate cancer. 68 Ga PSMA PET/CT scan is advanced and a promising radioligand has high sensitivity in determining lesions of prostate cancer with a high tumor to background ratio. The most common areas of metastasis are the bone and pelvic lymph nodes. The prognosis of prostate cancer is mainly determined by the status of metastases. The presence and the localization of metastases affects treatment planning. In our cases, we presented some examples of uncommon sites of metastases such as the brain, adrenal glands, penis and orbit. Improvements in imaging techniques, such as 68 Ga PSMA PET/CT have led to the possibility to make more determi nation of rare metastase sites in prostate cancer patients.